Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSStandard

TRYNGOLZA (AUTOINJECTOR)

OLEZARSEN SODIUM

Standard Dose
EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary

Approval overview TRYNGOLZA (AUTOINJECTOR) is listed in Drugs@FDA under application 218614 (NDA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient OLEZARSEN SODIUM Form and strength SOLUTION;SUBCUTANEOUS - EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML) Sponsor IONIS PHARMS INC Submission history Latest submission status date: 2024-12-19 00:00:00.

Structured Monograph

Clinical summary

Approval overview TRYNGOLZA (AUTOINJECTOR) is listed in Drugs@FDA under application 218614 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient OLEZARSEN SODIUM Form and strength SOLUTION;SUBCUTANEOUS - EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML) Sponsor IONIS PHARMS INC Submission history Latest submission status date: 2024-12-19 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.